Treating Cancer with Precision |

Treating Cancer with Precision

Cancer is a Disease of the Genome

Of the 20,000 genes that make up the human genome, about 400 genes are known to be highly associated with cancer. If mutations occur in genes that control important functions such as cell growth, it can cause cells to multiply out of control, leading to tumor formation.

With cancer genomic testing, now we can quickly decode the tumor DNA and identify cancer-related mutations. Knowing the mutations that drive the patient's cancer empowers the physicians to tailor treatment options for each patient.

Finding the Right Treatment for You

Patients with the same type of cancer often carry different genetic mutations, so two lung cancer patients may need different treatments because their tumors have different genetic mutations. Comprehensive genomic profiling allows physicians to identify the optimal treatment for each patient. This patient-specific approach is called “precision medicine.”

More Options, with Better Precision

Genomic profiling can sometimes find more treatment options for patients. Because patients of different cancer types may carry the same cancer-causing mutations, a drug approved for breast cancer, for example, may benefit a lung cancer patient who has a genetic alteration more commonly seen in breast cancer.

Cancer management is highly complex. In addition to genomic profiles, the physician needs to consider many factors including the patient's conditions and treatment history. It is therefore essential to discuss with your doctor and have your doctor comprehensively evaluate whether genomic testing is right for you. You can also contact us to learn more.

Cancer Treatment

How does genomic testing find the best treatment for me?

Genomic testing can identify the mutations that drive the patient's tumor growth. Since patients of the same cancer type often carry different mutations, genomic testing allows doctors to select the optimal treatments based on the individual's genomic profile. On the other hand, patients with different cancer types may harbor the same genetic mutations, so genomic profiling can sometimes identify more treatment options across cancer types. For example, a drug approved for breast cancer may benefit a lung cancer patient carrying a genetic alteration more commonly seen in breast cancer.

Is immunotherapy right for me?

Immunotherapy has shown impressive and durable results on some patients. However, the biggest challenge immunotherapy faces is its low response rate, with only about 20% of patients responding to treatment. It is therefore critical to identify patients who are likely to benefit in advance. ACTOnco^® + comprehensive genomic profiling can predict response to immunotherapy, helping doctors evaluate whether immunotherapy is right for you.

Comprehensive Genomic Profiling

For all solid tumors
Evaluates targeted, immune, hormone and chemo therapy
Predicts immunotherapy responses
Screens 440 cancer-related genes + 13 fusion genes & more than 350 transcripts

Targeted Genomic Profiling

For lung cancer and other solid tumors
Evaluates targeted therapy
Screens 40 druggable genes + 13 fusion genes & more than 350 transcripts

Fusion Gene Testing

For all solid tumors
Evaluates targeted therapy
Screens 13 fusion genes & more than 350 transcripts

DNA Repair Gene Testing

For ovarian cancer, prostate, breast cancer and other solid tumors
Evaluates PARP inhibitors treatment
Screens BRCA1/2 and HRR related genes

BRCA1/2 Gene Testing

For ovarian cancer, breast cancer and other solid tumors
Evaluates PARP inhibitors treatment
Screens BRCA1/2 genes

Brain Metastases Gene Testing

For lung cancer and other solid tumors
Evaluates targeted therapy
Screens 40 druggable genes

Cancer Monitoring

How do I monitor my cancer?

Cancer needs to be monitored during and after treatment to detect residual cancer after surgery, monitor if the tumor is shrinking, and check for drug resistance or cancer recurrence. Traditional ways to monitor cancer include detecting tumor proteins levels, such as the CEA or CA-125 tests, and conducting imaging examinations such as CT scans. A new way to monitor cancer is to detect tumor DNA circulating in the blood, called ctDNA (Circulating tumor DNA).

Through a simple blood test, ACTMonitor^®+ genomic testing analyzes the tumor DNA to look for genetic mutations correlated with drug resistance, assess if treatments are working, and detect cancer recurrence earlier than traditional methods.

Cancer Monitoring

Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses

Cancer Prevention

Have I inherited genetic mutations related to cancer?

Approximately 5-10% of cancers are hereditary, and the most common hereditary cancers are breast, colorectal, ovarian, prostate, pancreatic and kidney cancer. Hereditary cancers are caused by mutations in cancer-related genes, such as BRCA1/2. Understanding the hereditary cancer risk enables high-risk individuals to start taking actions for cancer prevention and early detection.

ACTRisk™is a genetic test that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with high-risk individuals.

Hereditary Risk Evaluation

Analyzes 67 genes
Evaluates risk for9 hereditary cancers and 11 cancer syndrome

Service Overview

Service	Why? (Purpose)	Who? (Design for)	What? (Tested Genes)	When? (Turnaround Time)	How? (Sample Requirement)
ACTOnco^®+	Comprehensive genomic profiling that evaluates chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy drugs	All solid tumors Diagnosed with advanced cancer or late-stage cancer Patient searching for treatment (and trials) options Recurrent and metastastic cases Newly diagnosed with complex cancer type	Comprehensive genomic profiling for 440 cancer-related genes, 13 fusion genes & more than 350 fusion transcripts	10 Working Days	FFPE Core needle biopsy Pleural effusion Ascites samples Pericardial hydrops
ACTDrug^®+	Provides tailored drug options	Patients who are newly diagnosed with cancer Patients who are evaluating targeted therapy treatment	Genomic profiling for 40 druggable genes, 13 fusion genes & more than 350 fusion transcripts	8 Working Days	FFPE Core needle biopsy Pleural effusion Ascites samples Pericardial hydrops
ACTFusion™	Provides fusion gene-related targeted treatment options	All solid tumor patients who are evaluating targeted therapy treatment	Genomic profiling for 13 fusion genes & more than 350 fusion transcripts	10 Working Days	FFPE Core needle biopsy Pleural effusion Ascites samples Pericardial hydrops
ACTLung™	Provides fusion gene-related targeted treatment options	Newly diagnosed with lung cancer	Genomic profiling for 13 lung cancer related-genes	8 Working Days	FFPE Core needle biopsy
ACTBRCA^®	Detects genetic alterations to evaluate PARP inhibitors	Breast Cancer Patients Ovarian Cancer Patients Other solid tumor patients who wish to use PARP inhibitors	Genomic profiling for BRCA1/2	10 Working Days	FFPE Blood
ACTHRD™	Detects genetic alterations to evaluate PARP inhibitors	Breast Cancer Patients Ovarian Cancer Patients Other solid tumor patients who wish to use PARP inhibitors	Genomic profiling for 24 genes (Including BRCA1/2 and other DNA repair genes)	10 Working Days	FFPE
ACTCerebra™	Provides targeted treatment options	All solid tumor patients who have brain metastases	Genomic profiling for 40 druggable genes	9 Working Days	Cerebrospinal fluid
ACTMonitor^®+	Monitors cancer recurrence and drug resistance	Patients with solid tumor unsuitable for surgery Patients with solid tumor and have developed drug resistance Patients with solid tumor and risk of cancer recurrence Patients with solid tumor and wish to monitor treatment response	Sequencing from 8-50 genes (optionable panels for specific cancer types)	10 Working Days	Blood Cerebrospinal fluid
ACTRisk™	Identifies genetic alterations related to hereditary cancer	Multiple family members who have cancer Any individual who is concerned about the inherent risk of hereditary cancers and cancer syndromes A family member who has multiple cancers, an early-onset cancer, or a rare cancer	Sequencing 67 hereditary cancer related genes	15 Working Days	Whole blood (PBMC)

1 Turnaround time is counted after the received sample passes ACT Genomics sample quality control test

2 Formalin-fixed and paraffin-embedded (FFPE)

3 Peripheral blood mononuclear cell (PBMC)

Q&A

Understanding Precision Medicine

What are genes?

Genes are DNA sequences that carry hereditary information. This information defines the traits of a cell and is necessary to maintain normal cell functions. Humans have approximately 20,000 genes.

What are gene mutations?

A gene mutation is a permanent change in the sequence of chemical bases in a cell’s DNA. Mutations occur frequently in the human body. Some mutations are not harmful, but other mutations may cause the proteins encoded by the gene to function incorrectly or not at all. This, in turn, prevents the cell from working properly and can cause diseases such as cancer.

How do gene mutations cause cancer and why do they influence therapy outcomes?

Among the 20,000 human genes, about 300-400 are related to cancer. If a mutation occurs in one of those genes, this may cause an uncontrolled growth of the affected cell by a dysregulation of the cell growth signaling pathway in which the mutated gene plays a role. Since patients have their own individual mutation patterns affecting different genes and pathways, targeted therapy only works for patients in which the targeted pathways are altered.

How can precision medicine identify the most effective treatment for me?

Precision medicine analyzes mutations in cancer-related genes to find out what drives your cancer, enabling the identification of targeted therapies that directly interfere with tumor growth. Because gene mutations are different for individual patients, you are more likely to benefit from therapies that are tailored for your cancer.

How is cancer genomic testing performed?

The mutations in cancer-related genes are identified by an analysis of tumor samples using a high-throughput method called next-generation sequencing (NGS). This method allows a rapid and comprehensive gene analysis. Through bioinformatics data processing and utilizing clinical databases, gene mutations are matched with the appropriate targeted therapies to provide patients and doctors with personalized treatment options.

Patients